Research programme: Alzheimer's disease vaccines - Pharmexa/Lundbeck
Alternative Names: Alzheimer's-disease-vaccine; ME 106; PX106Latest Information Update: 21 Dec 2007
At a glance
- Originator Pharmexa
- Class Alzheimer vaccines; Antidementias; Neuroprotectants; Vaccines
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 14 Dec 2007 Preclinical development is ongoing in Denmark
- 14 Dec 2007 Lundbeck and Pharmexa extend and update their license agreement
- 25 Nov 2005 This programme is still in active development for Alzheimer's disease